Treatment of Parkinson's disease with NADH
Abstract
It has earlier been claimed that clinical improvement of patients with Parkinson's disease is obtained by treatment with NADH. This has to be verified by double-blind, clinical studies and measurement of biochemical effects of the treatment. In a double blind study five patients with clinically moderate Parkinson's disease were treated with NADH, 25 mg, given intravenously once a day for four days. Then they were given 25 mg NADH intramuscularly after 2 and 4 weeks. Disability scores were determined before each treatment and two weeks after the final injection. A control group (n = 4) with the same degree of Parkinson's disease obtained sodium chloride with the same schedule. According to the Unified Parkinson's Disease Rating Scale a tendency to clinical improvement was seen after the iv infusions in both treatment and placebo groups. However, the changes were not statistically significant, and no changes occurred during the following weeks. No changes were found neither in the study nor the control group regarding cerebrospinal fluid concentrations of dynorfin, metenkefalin, somatostatin, hydroxy-methoxy-phenylglycol, homovanillic acid and 5-hydroxyindole acetic acid. The results indicate that no great changes are obtained after short-term treatment of parkinsonian patients with NADH, neither clinically nor biochemically.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A double-blinded study of 5 clinically moderate PD patients found no benefit from NADH given intravenously at 25 mg once daily for 4 days and then intramuscularly after 2 and 4 weeks.
“benefits were not seen in a double-blinded study on 5 clinically moderate PD patients treated with NADH (25 mg) given intravenously once a day for 4 days followed by NADH (25 mg) given intramuscularly after 2 and 4 weeks”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Dizdar et al., 1994
The Dizdar et al. PD study was double-blinded.
“double-blinded study on 5 clinically moderate PD patients”
From NAD+ in Brain Aging and Neurodegenerative Disorders (2019) · cites this paper as Dizdar et al., 1994
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · see citing works
Ehringer, H., & Hornykiewicz, O. (1960) · Journal of Molecular Medicine · doi:10.1007/bf01485901 · Cited by 1,875 · see citing works
BIOSYNTHESIS AND METABOLISM OF TETRAHYDROBIOPTERIN AND MOLYBDOPTERIN
Nichol, C. A., Smith, G. K., & Duch, D. S. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.003501 · Cited by 551 · see citing works
Solubilization and Partial Purification of Tyrosine Hydroxylase from Bovine Adrenal Medulla
Shiman, R., Akino, M., & Kaufman, S. (1971) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76979-8 · Cited by 411 · see citing works
DISTRIBUTION OF TYROSINE HYDROXYLASE IN HUMAN AND ANIMAL BRAIN1
McGeer, E. G., McGeer, P. L., & Wada, J. (1971) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1971.tb03738.x · Cited by 154 · see citing works
Nagatsu, T., Yamaguchi, T., Kato, T., Sugimoto, T., Matsuura, S., Akino, M., Nagatsu, I., Iizuka, R., & Narabayashi, H. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90316-8 · Cited by 117 · see citing works
Birkmayer, J. G. D., Vrecko, C., Volc, D., & Birkmayer, W. (1993) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb00018.x · Cited by 94 · see citing works
Significance of mitochondrial DNA deletions in myotonic dystrophy
Thyagarajan, D. E., Byrne, E., Noer, S., et al. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1993.tb04071.x · Cited by 19 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
NAD+ in Brain Aging and Neurodegenerative Disorders
Lautrup, S., Sinclair, D. A., Mattson, M. P., & Fang, E. F. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.001 · Cited by 790 · see citing works
Lloret, A., & Beal, M. F. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02809-1 · Cited by 52 · see citing works
- Authors
- Dizdar, N., Kågedal, B., & Lindvall, B.
- Affiliations
- Linköping University Hospital (SE)
- Corresponding author
- Dizdar, N.
- Venue
- Acta Neurologica Scandinavica
- Publisher
- Hindawi Limited
- Published
- 2009-01-29
- Volume
- 90
- Issue
- 5
- Pages
- 345-347
- ISSN
- 0001-6314 (ISSN-L)
- 1600-0404
- OpenAlex
- W2028246911
- Cited by
- 20
- References
- 8
- Citations by year
- 2026: 1 · 2023: 2 · 2020: 2 · 2019: 3 · 2018: 1 · 2014: 3
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Neurologica Scandinavica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Keywords
- Parkinson's disease, NADH, Unified Parkinson's Disease Rating Scale, disability score, cerebrospinal fluid biomarkers, dynorphin, met-enkephalin, somatostatin, homovanillic acid, 5-hydroxyindoleacetic acid, short-term treatment
- MeSH terms
- Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Humans, Infusions, Intravenous, Injections, Intramuscular, NAD, Neurologic Examination, Parkinson Disease, Pilot Projects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
